Roots Analysis has conducted an in-depth research on RNA therapeutics, analyzing the market landscape and affiliated products, to develop a detailed and informed perspective regarding the associated opportunity
Key Market Insights
- Foreseeing opportunities associated with the RNA therapeutics market, numerous start-ups have been established in the last few years
- At present, more than 50 companies are actively engaged in the development of RNA therapeutics; over 30% of such players have been established post-2016
- With over 290 RNA therapeutic candidates, including several in early stages of development, the current landscape is witnessing significant growth
- Based on our proprietary company health indexing approach, we awarded an overall company strength score, which is indicative of the relative strength of an innovator company involved in the field of RNA therapeutics
- RNA therapeutics have exhibited the potential to treat disorders which were previously deemed to be undruggable; this notion has increased the value proposition of businesses active in this market
- In pursuit of building a competitive edge, stakeholders are actively upgrading their existing capabilities and enhancing their respective product offerings, to comply with the evolving industry benchmarks
- Having realized the opportunity associated within RNA therapeutics market, several industry and non-industry players have collectively invested a sum of around USD 16 billion, since 2011
- The confidence of the general public in such personalized therapeutics and their respective developers is increasing; this is validated by the capital raised through public offerings
- Companies have raised significant capital through venture capital and secondary offerings, which represent 71% of the total amount invested
- An in-depth analysis of publicly disclosed financial statements, including product sales and earnings, provides valuable insights into a company's competitive position in the market
- Financial ratios provide a deeper perspective into the firm’s current and likely future capability to grow and thrive amidst the evolving competition in the industry
- Technical analysis of the historical price of a security and volume traded helps traders / investors predict future changes in value and thereby, make meaningful buy and sell decisions
- A variety of indicators have been used in order to scrutinize the supply and demand dynamics related to a security, which is believed to influence changes in price, volume and volatility of a stock
- The market’s evolution is likely to be driven by the rising need for novel drug candidates; we expect the future opportunity to be well distributed across different types of therapies therapeutic areas and key regions
- Using our proprietary approach, based on strength and qualitative understanding of value offered, we shortlisted several companies as potential acquisition targets for RNA therapeutics investors seeking to tap into the opportunity in this domain
- RNA therapeutic (public) ventures adopt varying strategies and continually monitor both internal and external risk parameters, in order to detect anomalies as early as possible
- Investors that have entered the RNA therapeutics market during the onset of the internet revolution, have reported multifold capital gains, resulting in a strong spur in investment activity in this domain
Table of Contents
EXCEL DELIVERABLE
1. INNOVATORS AND PRODUCTS DATASET
1.1. Analysis Notes
1.2. Innovators Landscape
1.3. Products Landscape
1.4. Value Proposition
1.5. Key Acquisition Targets
1.6. Appendices
2. FUNDING AND INVESTMENT ANALYSIS
2.1. Analysis Notes
2.2. Summary Dashboard
2.3. Capital Investments in RNA Therapeutics
2.4 Appendices
3. COMPANY VALUATION ANALYSIS
3.1. Analysis Notes
3.2. Sample Data Analysis
3.3. Company Valuation
3.4. Appendices
4. FUNDAMENTAL FINANCIAL ANALYSIS
4.1. Analysis Notes
4.2. Summary Dashboard
4.3. Company Fundamentals
4.4. Fundamental Analysis
4.5. Appendices
5. TECHNICAL FINANCIAL ANALYSIS
5.1. Analysis Notes
5.2. Key Highlights
5.3. Open High Low Close Chart / Stock Price & Volume Traded (Last 100 Days)
5.4. 5 Day Moving Average (Buy & Sell Signals)
5.5. 10 Day Moving Average (Buy & Sell Signals)
5.6. 50 Day Moving Average (Buy & Sell Signals)
5.7. Bollinger Bands®
5.8. Relative Strength Index
5.9. Average Directional Index
5.10. Commodity Channel Index
5.11. Williams R
5.12. Moving Average Convergence Divergence (MACD)
5.13. Appendices
6. BUSINESS RISK ASSESSMENT
6.1. Analysis Notes
6.2. Business Risk Data
6.3. Appendices
7. MARKET FORECAST AND OPPORTUNITY ANALYSIS
7.1. Analysis Notes
7.2. Market Forecast and Opportunity Analysis: Summary
7.3. Market Forecast and Opportunity Analysis: Base Scenario
7.4. Market Forecast and Opportunity Analysis: Conservative Scenario
7.5. Market Forecast and Opportunity Analysis: Optimistic Scenario
8. ANALYSIS OF RETURNS ON INVESTMENT
8.1. Analysis Notes
8.2. Estimated RoI for Investors in Company A
8.3. Estimated RoI for Investors in Company B
8.4. Estimated RoI for Investors in Company C
POWERPOINT DELIVERABLE
1. CONTEXT
2. PROJECT APPROACH
3. PROJECT OBJECTIVES
4. EXECUTIVE SUMMARY
Section I: Introduction to RNA Therapeutics and Innovators Landscape
5. THE RNA THERAPEUTICS MARKET
5.1. Overview
5.2. Types of RNA Therapeutics
5.3. Historical Development
5.4. Applications of RNA Therapeutics
5.5. Benefits of RNA Therapeutics
5.6. Challenges Associated with RNA Therapeutics
6. RNA THERAPEUTICS: INNOVATORS LANDSCAPE
6.1. Methodology
6.2. Innovators in the RNA Therapeutics Market
6.3. Analysis of Innovators Landscape
6.4. Concluding Remarks
7. RNA THERAPEUTICS: PRODUCTS LANDSCAPE AND COMPANY HEALTH INDEXING
7.1. List of RNA Therapeutics
7.2. Analysis of Products Landscape
7.3. Company Health Indexing Methodology
7.4. Company Health Indexing Scoring
7.5. Company Health Indexing
8. VALUE PROPOSITION ANALYSIS
8.1. Overview and Methodology
8.2. Value Proposition Analysis: Therapy-related Aspect
8.3. Value Proposition Analysis: Developer-related Aspect
8.4. Value Proposition Analysis: Technology-related Aspect
8.5. Value Proposition Analysis: Patient-related Aspect
8.6. Concluding Remarks
9. COMPANY COMPETITIVENESS ANALYSIS
9.1. Overview and Methodology
9.2. Company Competitiveness Analysis
9.3. Concluding Remarks
Section II: Analysis of Investments and Company Valuation
10. FUNDING AND INVESTMENT ANALYSIS
10.1. Overview
10.2. Analysis by Type of Funding
10.3. Analysis by Geography and Most Active Companies
10.4. Analysis of Trends Associated with Individual Funding Categories
10.5. RNA therapeutics funding and RNA therapeutics Investment Summary
11. COMPANY VALUATION ANALYSIS
11.1. Overview and Methodology
11.2. Company Valuation: Sample Dataset
11.3. Company Valuation: Based on Company Size
11.4. Company Valuation: Based on Latest Stage of Financing
11.5. Company Valuation: Concluding Remarks
Section III: Financial Analysis and Assessment of Business Risks
12. FINANCIAL ANALYSIS OF PUBLIC VENTURES
12.1. Fundamental Financial Analysis Overview
12.2. Financial Ratios (Interpretation Guide)
12.3. Fundamental Financial Analysis: List of Public Companies
12.4. Case Study 1
12.5. Technical Financial Analysis Overview
12.6. Technical Indicators (Interpretation Guide)
12.7. Technical Financial Analysis: List of Public Companies
12.8. Case Study 2
13. COMPANY PROFILES OF PUBLIC VENTURES
13.1. Arcturus Therapeutics
13.2. Ascletis Pharma
13.2.1. Key Highlights
13.2.1.1. Company Overview
13.2.1.2. Insights from Balance Sheet
13.2.1.3. Key Executive Team
13.2.1.4. Recent Developments
13.2.2. Key Financial Details
13.2.2.1. Company Investments
13.2.2.2. Company Fundamentals
13.2.2.3. Company Technicals
13.3. Avidity Biosciences
13.4. BioNtech
13.5. CanSino Biologics
13.6. Gritstone bio
13.7. IVERIC bio
13.8. Moderna
13.9. Phio Pharmaceuticals
13.10. Vir Biotechnology
14. BUSINESS RISK ASSESSMENT
14.1. Overview and Methodology
14.2. Operations-related Risks
14.3. Business-related Risks
14.4. Financial / Asset-related Risks
14.5. Product / Technology-related Risks
14.6. Other Risks
14.7. Summary of Business Risk Assessment
Section IV: Market Forecast and Opportunity Analysis
15. MARKET FORECAST AND OPPORTUNITY ANALYSIS
15.1. Overview and Methodology
15.2. Global RNA Therapeutics Market, 2023-2035
Section V: Analysis of Returns on Investment and Key Acquisition Targets
16. ANALYSIS OF RETURNS ON INVESTMENT
16.1. Overview and Methodology
16.2. Case Studies
17. KEY ACQUISITION TARGETS
17.1. Overview and Methodology
17.2. Likely Acquisition Targets
18. CONCLUSION
19. APPENDICES
To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/opportunities-in-rna-therapeutics-market.html
Learn from experts: do you know about these emerging industry trends?
Applications of Blockchain in Various Sectors: An Introduction
Intracellular Drug Delivery – Future Potential
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Learn more about Roots Analysis consulting services:
Roots Analysis Consulting - the preferred research partner for global firms
Contact:
Ben Johnson
+1 (415) 800 3415
